initial public offerings (IPOs) trading on American exchanges

Sunday, August 16, 2020

CureVac (CVAC) began trading on the Nasdaq on Fri 14 Aug 2020

CureVac priced 13.3 mln share IPO at $16, the high end of the $14-$16 expected price range
CureVac BV raised $213 million in its initial public offering (IPO) in New York on Thursday, setting the stage for the first stock market debut of a company developing a promising vaccine to combat the coronavirus.

  • The big draw is its mRNA COVID-19 vaccine candidate, currently in Phase 1 development. Topline data should be available next quarter.
  • Lead program is CV8102, also in Phase 1 development, for the treatment of four types of solid tumors.
  • Earlier this year, CureVac tapped investors, including the German government and GSK, for $640M to support its work against the coronavirus and other diseases.

No comments:

Post a Comment